Krystal Biotech Inc (KRYS) — Cash Flow Quality Index
Krystal Biotech Inc (KRYS) has a Cash Flow Quality Index of 1.44x as of March 2026. Operating cash flow of $80.38 Million exceeds net income of $55.93 Million, indicating high earnings quality where cash backs reported profits. Explore Krystal Biotech Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Krystal Biotech Inc Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Krystal Biotech Inc across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check KRYS goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Krystal Biotech Inc (2023–2025)
Year-by-year earnings quality comparison for Krystal Biotech Inc. For live market cap and the full company financial profile, see Krystal Biotech Inc (KRYS) total market value.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.98x | $200.87 Million | $204.83 Million | ▼ -29.2% |
| 2024 | 1.38x | $123.42 Million | $89.16 Million | ▲ +117.0% |
| 2023 | -8.12x | $-88.80 Million | $10.93 Million | — |